Credit Suisse Group AG cut shares of Diplomat Pharmacy Inc. (NYSE:DPLO) from a neutral rating to an underperform rating in a report published on Wednesday. Credit Suisse Group AG currently has $13.00 price target on the stock, down from their previous price target of $18.00.
Other equities analysts have also recently issued research reports about the stock. Mizuho reduced their price target on shares of Diplomat Pharmacy from $39.00 to $17.00 and set a neutral rating on the stock in a research report on Thursday, November 3rd. Raymond James Financial Inc. restated a market perform rating on shares of Diplomat Pharmacy in a report on Thursday, November 3rd. Avondale Partners cut shares of Diplomat Pharmacy from an outperform rating to a market perform rating in a report on Thursday, November 3rd. Zacks Investment Research cut shares of Diplomat Pharmacy from a buy rating to a hold rating in a report on Thursday, August 11th. Finally, Citigroup Inc. cut shares of Diplomat Pharmacy to a market perform rating in a report on Thursday, November 3rd. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the stock. Diplomat Pharmacy presently has an average rating of Hold and an average target price of $26.00.
Shares of Diplomat Pharmacy (NYSE:DPLO) opened at 15.03 on Wednesday. The stock’s 50 day moving average is $21.08 and its 200 day moving average is $30.03. The stock has a market cap of $999.66 million, a price-to-earnings ratio of 30.99 and a beta of 1.21. Diplomat Pharmacy has a 52 week low of $12.47 and a 52 week high of $38.94.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by $0.03. Diplomat Pharmacy had a net margin of 0.77% and a return on equity of 10.47%. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.26 billion. During the same quarter in the prior year, the firm earned $0.26 EPS. Diplomat Pharmacy’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities analysts forecast that Diplomat Pharmacy will post $0.84 EPS for the current year.
In related news, EVP Atheer A. Kaddis sold 20,000 shares of the stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $30.12, for a total transaction of $602,400.00. Following the transaction, the executive vice president now owns 20,000 shares in the company, valued at $602,400. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 35.40% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Diplomat Pharmacy by 9.5% in the second quarter. Vanguard Group Inc. now owns 3,334,010 shares of the company’s stock worth $116,690,000 after buying an additional 289,571 shares during the period. BlackRock Fund Advisors increased its position in shares of Diplomat Pharmacy by 18.3% in the third quarter. BlackRock Fund Advisors now owns 3,180,902 shares of the company’s stock worth $89,097,000 after buying an additional 492,922 shares during the period. Wells Fargo & Company MN increased its position in shares of Diplomat Pharmacy by 2.2% in the third quarter. Wells Fargo & Company MN now owns 2,493,518 shares of the company’s stock worth $69,843,000 after buying an additional 54,413 shares during the period. Capital World Investors increased its position in shares of Diplomat Pharmacy by 21.3% in the third quarter. Capital World Investors now owns 2,385,000 shares of the company’s stock worth $66,804,000 after buying an additional 418,400 shares during the period. Finally, TimesSquare Capital Management LLC increased its position in shares of Diplomat Pharmacy by 11.3% in the third quarter. TimesSquare Capital Management LLC now owns 1,561,700 shares of the company’s stock worth $43,743,000 after buying an additional 158,245 shares during the period. Institutional investors own 77.02% of the company’s stock.
About Diplomat Pharmacy